Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
Kyverna Therapeutics, Inc. (KYTX) Stock Price & Analysis
36 Followers
KYTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.96 - $35.06
Previous Close$15.25
Volume459.65K
Average Volume (3M)504.29K
Market Cap
$657.51M
Enterprise Value$609.04M
Total Cash (Recent Filing)$57.54M
Total Debt (Recent Filing)$9.08M
Price to Earnings (P/E)N/A
Beta-0.15
Next Earnings
Mar 26, 2024EPS Estimate
-$0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding43,115,244
10 Day Avg. Volume502,349
30 Day Avg. Volume504,289
Standard Deviation0.22
R-Squared1.00
Alpha-0.22
Financial Highlights & Ratios
Price to Book (P/B)-4.93
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$41.00Price Target Upside168.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Kyverna Therapeutics, Inc. News
Ownership Overview
49.45% Insiders
1.33% Mutual Funds
14.56% Other Institutional Investors
34.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $13.96 and its highest was $35.06 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is Mar 26, 2024 which is 43 days ago.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -$0.7.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 43,115,246 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
---
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (168.85% Upside)
$41.00 (168.85% Upside)
Insider Transactions
Bought Shares
Worth $45.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.8%
Last 30 Days ▲ 24.6%
Last 30 Days ▲ 24.6%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.36%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna¿s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.
---
KYTX Stock 12 Month Forecast
Average Price Target
$41.00
▲(168.85% Upside)
Technical Analysis
Best Analysts Covering KYTX
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-38.45%
reiterated a buy rating 23 days ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.45% per trade.
---